nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—ABCB1—Lisinopril—dilated cardiomyopathy	0.178	0.532	CbGbCtD
Terazosin—ABCB1—Spironolactone—dilated cardiomyopathy	0.156	0.468	CbGbCtD
Terazosin—KCNH2—purkinje fiber—dilated cardiomyopathy	0.121	0.59	CbGeAlD
Terazosin—KCNH2—endocardium—dilated cardiomyopathy	0.0625	0.304	CbGeAlD
Terazosin—Shoulder pain—Lisinopril—dilated cardiomyopathy	0.0127	0.0406	CcSEcCtD
Terazosin—Hypotensive—Furosemide—dilated cardiomyopathy	0.0125	0.04	CcSEcCtD
Terazosin—Gastritis—Spironolactone—dilated cardiomyopathy	0.00537	0.0172	CcSEcCtD
Terazosin—KCNH2—cardiac ventricle—dilated cardiomyopathy	0.00526	0.0256	CbGeAlD
Terazosin—KCNH2—myocardium—dilated cardiomyopathy	0.00495	0.0241	CbGeAlD
Terazosin—Gout—Furosemide—dilated cardiomyopathy	0.00487	0.0156	CcSEcCtD
Terazosin—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00483	0.0155	CcSEcCtD
Terazosin—ADRA1A—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.00448	0.0302	CbGpPWpGaD
Terazosin—KCNH2—Hematopoietic Stem Cell Differentiation—CSF3—dilated cardiomyopathy	0.00423	0.0285	CbGpPWpGaD
Terazosin—ADRA1B—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00409	0.0276	CbGpPWpGaD
Terazosin—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00376	0.0121	CcSEcCtD
Terazosin—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00375	0.012	CcSEcCtD
Terazosin—Cough increased—Lisinopril—dilated cardiomyopathy	0.00373	0.012	CcSEcCtD
Terazosin—Gout—Lisinopril—dilated cardiomyopathy	0.00366	0.0117	CcSEcCtD
Terazosin—ADRA1A—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00363	0.0245	CbGpPWpGaD
Terazosin—ADRA1A—heart—dilated cardiomyopathy	0.00358	0.0174	CbGeAlD
Terazosin—KCNH2—heart—dilated cardiomyopathy	0.00346	0.0168	CbGeAlD
Terazosin—Neck pain—Lisinopril—dilated cardiomyopathy	0.00346	0.0111	CcSEcCtD
Terazosin—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00346	0.0111	CcSEcCtD
Terazosin—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00341	0.0109	CcSEcCtD
Terazosin—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00339	0.0109	CcSEcCtD
Terazosin—Malaise—Spironolactone—dilated cardiomyopathy	0.0033	0.0106	CcSEcCtD
Terazosin—Discomfort—Spironolactone—dilated cardiomyopathy	0.00308	0.00986	CcSEcCtD
Terazosin—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00302	0.00967	CcSEcCtD
Terazosin—Confusional state—Spironolactone—dilated cardiomyopathy	0.00301	0.00965	CcSEcCtD
Terazosin—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00301	0.00964	CcSEcCtD
Terazosin—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00298	0.00957	CcSEcCtD
Terazosin—KCNH2—cardiac atrium—dilated cardiomyopathy	0.00296	0.0144	CbGeAlD
Terazosin—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00292	0.00937	CcSEcCtD
Terazosin—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00282	0.00905	CcSEcCtD
Terazosin—KCNH6—Neuronal System—ABCC9—dilated cardiomyopathy	0.00274	0.0185	CbGpPWpGaD
Terazosin—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00272	0.00872	CcSEcCtD
Terazosin—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00267	0.00857	CcSEcCtD
Terazosin—Somnolence—Spironolactone—dilated cardiomyopathy	0.00265	0.0085	CcSEcCtD
Terazosin—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00264	0.00845	CcSEcCtD
Terazosin—KCNH6—Neuronal System—ACTN2—dilated cardiomyopathy	0.00263	0.0177	CbGpPWpGaD
Terazosin—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00262	0.00838	CcSEcCtD
Terazosin—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00261	0.00835	CcSEcCtD
Terazosin—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00256	0.00821	CcSEcCtD
Terazosin—KCNH2—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00256	0.0173	CbGpPWpGaD
Terazosin—Arthritis—Lisinopril—dilated cardiomyopathy	0.00255	0.00817	CcSEcCtD
Terazosin—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00253	0.00811	CcSEcCtD
Terazosin—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00248	0.00794	CcSEcCtD
Terazosin—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00248	0.00794	CcSEcCtD
Terazosin—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00246	0.00788	CcSEcCtD
Terazosin—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00246	0.00788	CcSEcCtD
Terazosin—KCNH7—Neuronal System—ABCC9—dilated cardiomyopathy	0.00245	0.0165	CbGpPWpGaD
Terazosin—Sweating—Furosemide—dilated cardiomyopathy	0.00244	0.00782	CcSEcCtD
Terazosin—Face oedema—Lisinopril—dilated cardiomyopathy	0.00239	0.00767	CcSEcCtD
Terazosin—KCNH2—Potassium Channels—ABCC9—dilated cardiomyopathy	0.00237	0.016	CbGpPWpGaD
Terazosin—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00236	0.00756	CcSEcCtD
Terazosin—KCNH7—Neuronal System—ACTN2—dilated cardiomyopathy	0.00235	0.0158	CbGpPWpGaD
Terazosin—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00226	0.00726	CcSEcCtD
Terazosin—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00222	0.0071	CcSEcCtD
Terazosin—Visual impairment—Furosemide—dilated cardiomyopathy	0.0022	0.00706	CcSEcCtD
Terazosin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.0022	0.00705	CcSEcCtD
Terazosin—Gastritis—Lisinopril—dilated cardiomyopathy	0.00219	0.00703	CcSEcCtD
Terazosin—ADRA1D—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00215	0.0145	CbGpPWpGaD
Terazosin—Asthma—Lisinopril—dilated cardiomyopathy	0.00214	0.00687	CcSEcCtD
Terazosin—Influenza—Lisinopril—dilated cardiomyopathy	0.00214	0.00687	CcSEcCtD
Terazosin—Eye disorder—Furosemide—dilated cardiomyopathy	0.00214	0.00685	CcSEcCtD
Terazosin—Tinnitus—Furosemide—dilated cardiomyopathy	0.00213	0.00683	CcSEcCtD
Terazosin—Pruritus—Spironolactone—dilated cardiomyopathy	0.00211	0.00677	CcSEcCtD
Terazosin—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00209	0.00669	CcSEcCtD
Terazosin—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00206	0.0066	CcSEcCtD
Terazosin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00204	0.00654	CcSEcCtD
Terazosin—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00204	0.00654	CcSEcCtD
Terazosin—Dysuria—Lisinopril—dilated cardiomyopathy	0.002	0.00642	CcSEcCtD
Terazosin—Malnutrition—Furosemide—dilated cardiomyopathy	0.00199	0.00638	CcSEcCtD
Terazosin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00197	0.00633	CcSEcCtD
Terazosin—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00197	0.00632	CcSEcCtD
Terazosin—Flatulence—Furosemide—dilated cardiomyopathy	0.00196	0.00628	CcSEcCtD
Terazosin—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00196	0.00627	CcSEcCtD
Terazosin—Weight increased—Lisinopril—dilated cardiomyopathy	0.00195	0.00625	CcSEcCtD
Terazosin—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00195	0.00624	CcSEcCtD
Terazosin—Depression—Lisinopril—dilated cardiomyopathy	0.0019	0.0061	CcSEcCtD
Terazosin—Vomiting—Spironolactone—dilated cardiomyopathy	0.0019	0.00608	CcSEcCtD
Terazosin—Rash—Spironolactone—dilated cardiomyopathy	0.00188	0.00603	CcSEcCtD
Terazosin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00188	0.00603	CcSEcCtD
Terazosin—Vision blurred—Furosemide—dilated cardiomyopathy	0.00187	0.00601	CcSEcCtD
Terazosin—Headache—Spironolactone—dilated cardiomyopathy	0.00187	0.00599	CcSEcCtD
Terazosin—Jaundice—Lisinopril—dilated cardiomyopathy	0.00186	0.00597	CcSEcCtD
Terazosin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00186	0.00595	CcSEcCtD
Terazosin—Sweating—Lisinopril—dilated cardiomyopathy	0.00183	0.00587	CcSEcCtD
Terazosin—KCNH2—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00182	0.0123	CbGpPWpGaD
Terazosin—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00182	0.0123	CbGpPWpGaD
Terazosin—ADRA1D—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00181	0.0122	CbGpPWpGaD
Terazosin—Epistaxis—Lisinopril—dilated cardiomyopathy	0.0018	0.00577	CcSEcCtD
Terazosin—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00179	0.00574	CcSEcCtD
Terazosin—Vertigo—Furosemide—dilated cardiomyopathy	0.00179	0.00573	CcSEcCtD
Terazosin—ADRA1B—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00179	0.012	CbGpPWpGaD
Terazosin—Nausea—Spironolactone—dilated cardiomyopathy	0.00177	0.00568	CcSEcCtD
Terazosin—ADRA1D—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00174	0.0118	CbGpPWpGaD
Terazosin—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00172	0.00551	CcSEcCtD
Terazosin—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.0017	0.00545	CcSEcCtD
Terazosin—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00169	0.00541	CcSEcCtD
Terazosin—Dry mouth—Furosemide—dilated cardiomyopathy	0.00166	0.00531	CcSEcCtD
Terazosin—Confusional state—Furosemide—dilated cardiomyopathy	0.00164	0.00525	CcSEcCtD
Terazosin—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00162	0.0052	CcSEcCtD
Terazosin—Tinnitus—Lisinopril—dilated cardiomyopathy	0.0016	0.00512	CcSEcCtD
Terazosin—Shock—Furosemide—dilated cardiomyopathy	0.0016	0.00512	CcSEcCtD
Terazosin—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00159	0.0051	CcSEcCtD
Terazosin—ADRA1A—Endothelin Pathways—ADRB1—dilated cardiomyopathy	0.00159	0.0107	CbGpPWpGaD
Terazosin—ADRA1A—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00159	0.0107	CbGpPWpGaD
Terazosin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00157	0.00503	CcSEcCtD
Terazosin—Anorexia—Furosemide—dilated cardiomyopathy	0.00155	0.00496	CcSEcCtD
Terazosin—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00153	0.00491	CcSEcCtD
Terazosin—Hypotension—Furosemide—dilated cardiomyopathy	0.00152	0.00486	CcSEcCtD
Terazosin—ABCB1—heart—dilated cardiomyopathy	0.00152	0.00737	CbGeAlD
Terazosin—ADRA1B—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.0015	0.0101	CbGpPWpGaD
Terazosin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00149	0.00478	CcSEcCtD
Terazosin—Flatulence—Lisinopril—dilated cardiomyopathy	0.00147	0.00471	CcSEcCtD
Terazosin—ADRA1D—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00147	0.00988	CbGpPWpGaD
Terazosin—Tension—Lisinopril—dilated cardiomyopathy	0.00146	0.00469	CcSEcCtD
Terazosin—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00146	0.00469	CcSEcCtD
Terazosin—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00146	0.00467	CcSEcCtD
Terazosin—Nervousness—Lisinopril—dilated cardiomyopathy	0.00145	0.00465	CcSEcCtD
Terazosin—ADRA1B—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00145	0.00975	CbGpPWpGaD
Terazosin—Back pain—Lisinopril—dilated cardiomyopathy	0.00144	0.00463	CcSEcCtD
Terazosin—Somnolence—Furosemide—dilated cardiomyopathy	0.00144	0.00463	CcSEcCtD
Terazosin—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00141	0.00452	CcSEcCtD
Terazosin—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00141	0.00451	CcSEcCtD
Terazosin—Fatigue—Furosemide—dilated cardiomyopathy	0.0014	0.00449	CcSEcCtD
Terazosin—Tremor—Lisinopril—dilated cardiomyopathy	0.0014	0.00448	CcSEcCtD
Terazosin—Constipation—Furosemide—dilated cardiomyopathy	0.00139	0.00445	CcSEcCtD
Terazosin—Pain—Furosemide—dilated cardiomyopathy	0.00139	0.00445	CcSEcCtD
Terazosin—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00138	0.00444	CcSEcCtD
Terazosin—Angioedema—Lisinopril—dilated cardiomyopathy	0.00136	0.00437	CcSEcCtD
Terazosin—ADRA1D—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.00136	0.00918	CbGpPWpGaD
Terazosin—Malaise—Lisinopril—dilated cardiomyopathy	0.00135	0.00431	CcSEcCtD
Terazosin—Vertigo—Lisinopril—dilated cardiomyopathy	0.00134	0.0043	CcSEcCtD
Terazosin—Syncope—Lisinopril—dilated cardiomyopathy	0.00134	0.00429	CcSEcCtD
Terazosin—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00134	0.00429	CcSEcCtD
Terazosin—ADRA1A—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00133	0.00899	CbGpPWpGaD
Terazosin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00133	0.00426	CcSEcCtD
Terazosin—ADRA1D—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.00132	0.00893	CbGpPWpGaD
Terazosin—Palpitations—Lisinopril—dilated cardiomyopathy	0.00132	0.00423	CcSEcCtD
Terazosin—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00131	0.00421	CcSEcCtD
Terazosin—Cough—Lisinopril—dilated cardiomyopathy	0.0013	0.00418	CcSEcCtD
Terazosin—ADRA1A—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00129	0.00866	CbGpPWpGaD
Terazosin—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00128	0.00411	CcSEcCtD
Terazosin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00128	0.00411	CcSEcCtD
Terazosin—Myalgia—Lisinopril—dilated cardiomyopathy	0.00127	0.00407	CcSEcCtD
Terazosin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00127	0.00407	CcSEcCtD
Terazosin—Chest pain—Lisinopril—dilated cardiomyopathy	0.00127	0.00407	CcSEcCtD
Terazosin—Anxiety—Lisinopril—dilated cardiomyopathy	0.00127	0.00406	CcSEcCtD
Terazosin—Discomfort—Lisinopril—dilated cardiomyopathy	0.00126	0.00402	CcSEcCtD
Terazosin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00124	0.00398	CcSEcCtD
Terazosin—Confusional state—Lisinopril—dilated cardiomyopathy	0.00123	0.00394	CcSEcCtD
Terazosin—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00122	0.0039	CcSEcCtD
Terazosin—Oedema—Lisinopril—dilated cardiomyopathy	0.00122	0.0039	CcSEcCtD
Terazosin—ADRA1B—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00122	0.0082	CbGpPWpGaD
Terazosin—Shock—Lisinopril—dilated cardiomyopathy	0.0012	0.00384	CcSEcCtD
Terazosin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0012	0.00383	CcSEcCtD
Terazosin—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00119	0.00382	CcSEcCtD
Terazosin—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00119	0.00381	CcSEcCtD
Terazosin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00118	0.00377	CcSEcCtD
Terazosin—Asthenia—Furosemide—dilated cardiomyopathy	0.00116	0.00373	CcSEcCtD
Terazosin—Anorexia—Lisinopril—dilated cardiomyopathy	0.00116	0.00372	CcSEcCtD
Terazosin—Pruritus—Furosemide—dilated cardiomyopathy	0.00115	0.00368	CcSEcCtD
Terazosin—Hypotension—Lisinopril—dilated cardiomyopathy	0.00114	0.00365	CcSEcCtD
Terazosin—ADRA1B—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.00113	0.00762	CbGpPWpGaD
Terazosin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00111	0.00356	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00111	0.00356	CcSEcCtD
Terazosin—Insomnia—Lisinopril—dilated cardiomyopathy	0.0011	0.00353	CcSEcCtD
Terazosin—ADRA1B—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.0011	0.00741	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.0011	0.0074	CbGpPWpGaD
Terazosin—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00109	0.00351	CcSEcCtD
Terazosin—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00109	0.00348	CcSEcCtD
Terazosin—Somnolence—Lisinopril—dilated cardiomyopathy	0.00108	0.00347	CcSEcCtD
Terazosin—ADRA1A—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00108	0.00728	CbGpPWpGaD
Terazosin—Dizziness—Furosemide—dilated cardiomyopathy	0.00107	0.00344	CcSEcCtD
Terazosin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00107	0.00344	CcSEcCtD
Terazosin—KCNH7—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.00107	0.00719	CbGpPWpGaD
Terazosin—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00106	0.00339	CcSEcCtD
Terazosin—Fatigue—Lisinopril—dilated cardiomyopathy	0.00105	0.00337	CcSEcCtD
Terazosin—Pain—Lisinopril—dilated cardiomyopathy	0.00104	0.00334	CcSEcCtD
Terazosin—Constipation—Lisinopril—dilated cardiomyopathy	0.00104	0.00334	CcSEcCtD
Terazosin—KCNH2—Neuronal System—ABCC9—dilated cardiomyopathy	0.00104	0.00698	CbGpPWpGaD
Terazosin—Vomiting—Furosemide—dilated cardiomyopathy	0.00103	0.00331	CcSEcCtD
Terazosin—Rash—Furosemide—dilated cardiomyopathy	0.00102	0.00328	CcSEcCtD
Terazosin—Dermatitis—Furosemide—dilated cardiomyopathy	0.00102	0.00328	CcSEcCtD
Terazosin—Headache—Furosemide—dilated cardiomyopathy	0.00102	0.00326	CcSEcCtD
Terazosin—ADRA1A—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.001	0.00677	CbGpPWpGaD
Terazosin—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.001	0.00322	CcSEcCtD
Terazosin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000996	0.00319	CcSEcCtD
Terazosin—KCNH2—Neuronal System—ACTN2—dilated cardiomyopathy	0.000993	0.0067	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.000987	0.00665	CbGpPWpGaD
Terazosin—ADRA1A—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.000977	0.00658	CbGpPWpGaD
Terazosin—Nausea—Furosemide—dilated cardiomyopathy	0.000964	0.00309	CcSEcCtD
Terazosin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000963	0.00309	CcSEcCtD
Terazosin—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000963	0.00309	CcSEcCtD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000911	0.00614	CbGpPWpGaD
Terazosin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000897	0.00288	CcSEcCtD
Terazosin—Asthenia—Lisinopril—dilated cardiomyopathy	0.000874	0.0028	CcSEcCtD
Terazosin—Pruritus—Lisinopril—dilated cardiomyopathy	0.000862	0.00276	CcSEcCtD
Terazosin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000833	0.00267	CcSEcCtD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000809	0.00546	CbGpPWpGaD
Terazosin—Dizziness—Lisinopril—dilated cardiomyopathy	0.000805	0.00258	CcSEcCtD
Terazosin—Vomiting—Lisinopril—dilated cardiomyopathy	0.000774	0.00248	CcSEcCtD
Terazosin—ADRA1D—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.000774	0.00522	CbGpPWpGaD
Terazosin—Rash—Lisinopril—dilated cardiomyopathy	0.000768	0.00246	CcSEcCtD
Terazosin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000767	0.00246	CcSEcCtD
Terazosin—Headache—Lisinopril—dilated cardiomyopathy	0.000763	0.00245	CcSEcCtD
Terazosin—Nausea—Lisinopril—dilated cardiomyopathy	0.000724	0.00232	CcSEcCtD
Terazosin—KCNH2—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.000712	0.0048	CbGpPWpGaD
Terazosin—ADRA1D—G alpha (12/13) signalling events—RAC1—dilated cardiomyopathy	0.000702	0.00473	CbGpPWpGaD
Terazosin—ADRA1B—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.000689	0.00465	CbGpPWpGaD
Terazosin—ADRA1A—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.000661	0.00446	CbGpPWpGaD
Terazosin—ADRA1B—LPA receptor mediated events—RAC1—dilated cardiomyopathy	0.000661	0.00446	CbGpPWpGaD
Terazosin—ADRA1D—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000644	0.00434	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000617	0.00416	CbGpPWpGaD
Terazosin—ADRA1A—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.000612	0.00413	CbGpPWpGaD
Terazosin—KCNH6—Neuronal System—RAF1—dilated cardiomyopathy	0.000599	0.00404	CbGpPWpGaD
Terazosin—ADRA1B—G alpha (12/13) signalling events—RAC1—dilated cardiomyopathy	0.000582	0.00393	CbGpPWpGaD
Terazosin—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000535	0.0036	CbGpPWpGaD
Terazosin—KCNH7—Neuronal System—RAF1—dilated cardiomyopathy	0.000534	0.0036	CbGpPWpGaD
Terazosin—ADRA1D—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000532	0.00358	CbGpPWpGaD
Terazosin—ADRA1D—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000522	0.00352	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (12/13) signalling events—RAC1—dilated cardiomyopathy	0.000517	0.00349	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000514	0.00347	CbGpPWpGaD
Terazosin—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000475	0.0032	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000461	0.00311	CbGpPWpGaD
Terazosin—ADRA1D—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000459	0.00309	CbGpPWpGaD
Terazosin—ADRA1B—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000441	0.00297	CbGpPWpGaD
Terazosin—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000433	0.00292	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000433	0.00292	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000429	0.00289	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000415	0.0028	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00041	0.00277	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000395	0.00266	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000395	0.00266	CbGpPWpGaD
Terazosin—ADRA1A—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000392	0.00264	CbGpPWpGaD
Terazosin—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000385	0.00259	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000383	0.00258	CbGpPWpGaD
Terazosin—ADRA1B—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000381	0.00257	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000367	0.00248	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000363	0.00245	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000356	0.0024	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000356	0.0024	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000355	0.00239	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000345	0.00232	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00034	0.0023	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00034	0.00229	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000338	0.00228	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000337	0.00227	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000336	0.00227	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000328	0.00221	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000328	0.00221	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000325	0.00219	CbGpPWpGaD
Terazosin—ADRA1D—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000323	0.00218	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000316	0.00213	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000306	0.00206	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000305	0.00205	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000304	0.00205	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000302	0.00204	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000301	0.00203	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000301	0.00203	CbGpPWpGaD
Terazosin—ADRA1B—LPA receptor mediated events—EGFR—dilated cardiomyopathy	0.000301	0.00203	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000295	0.00199	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000294	0.00198	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000291	0.00196	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000291	0.00196	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000289	0.00195	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000288	0.00194	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00028	0.00189	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000279	0.00188	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000271	0.00183	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000271	0.00183	CbGpPWpGaD
Terazosin—ADRA1B—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000268	0.00181	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000262	0.00177	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000261	0.00176	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000252	0.0017	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00025	0.00168	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00025	0.00168	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000248	0.00167	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00024	0.00162	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000239	0.00161	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000238	0.0016	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000235	0.00158	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000232	0.00156	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000231	0.00156	CbGpPWpGaD
Terazosin—KCNH2—Neuronal System—RAF1—dilated cardiomyopathy	0.000226	0.00152	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000225	0.00152	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000224	0.00151	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000222	0.0015	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000222	0.0015	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000219	0.00148	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000214	0.00144	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000213	0.00143	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000212	0.00143	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00021	0.00142	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000206	0.00139	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000204	0.00138	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000204	0.00138	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.0002	0.00135	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.0002	0.00135	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000192	0.00129	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00019	0.00128	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000182	0.00123	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000177	0.0012	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000171	0.00115	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00017	0.00115	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00017	0.00115	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000166	0.00112	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000166	0.00112	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000163	0.0011	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000162	0.00109	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.00016	0.00108	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000158	0.00107	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000158	0.00106	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000157	0.00106	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000154	0.00104	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000154	0.00104	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000153	0.00103	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000148	0.000996	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000144	0.000968	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000141	0.000951	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000141	0.000951	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000139	0.000937	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000138	0.000931	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000138	0.00093	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000137	0.000926	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000135	0.000911	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000131	0.000884	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000131	0.000881	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.00013	0.000875	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000128	0.000864	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000128	0.000864	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000127	0.000856	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000125	0.000845	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000125	0.000845	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000124	0.000836	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.00012	0.000809	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000119	0.000803	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000119	0.0008	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000117	0.000791	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000117	0.000786	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000115	0.000778	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000114	0.000769	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000114	0.000767	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000114	0.000767	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000113	0.000761	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000113	0.000759	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000109	0.000731	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000106	0.000713	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000104	0.000703	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000103	0.000694	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000103	0.000692	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000102	0.000691	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000101	0.000683	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9.85e-05	0.000664	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.64e-05	0.00065	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.63e-05	0.000649	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	9.35e-05	0.00063	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.2e-05	0.00062	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.14e-05	0.000616	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.12e-05	0.000615	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.12e-05	0.000615	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.75e-05	0.00059	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.74e-05	0.000589	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.52e-05	0.000575	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.48e-05	0.000572	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AGT—dilated cardiomyopathy	8.35e-05	0.000563	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.3e-05	0.00056	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.21e-05	0.000554	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.99e-05	0.000539	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.64e-05	0.000515	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.57e-05	0.00051	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.57e-05	0.00051	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.57e-05	0.00051	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.26e-05	0.000489	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	7.15e-05	0.000482	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.1e-05	0.000479	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.04e-05	0.000474	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.01e-05	0.000473	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AGT—dilated cardiomyopathy	6.93e-05	0.000467	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.82e-05	0.000459	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	6.81e-05	0.000459	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.78e-05	0.000457	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.72e-05	0.000453	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.72e-05	0.000453	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.65e-05	0.000449	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.45e-05	0.000435	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.25e-05	0.000421	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	6.16e-05	0.000415	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.05e-05	0.000408	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.82e-05	0.000392	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.8e-05	0.000391	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.72e-05	0.000385	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.52e-05	0.000372	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.17e-05	0.000349	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RAC1—dilated cardiomyopathy	5.16e-05	0.000348	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AGT—dilated cardiomyopathy	4.93e-05	0.000333	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.9e-05	0.000331	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.81e-05	0.000324	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.74e-05	0.00032	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	4.29e-05	0.000289	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.27e-05	0.000288	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.21e-05	0.000284	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.14e-05	0.000279	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	4.1e-05	0.000276	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.98e-05	0.000268	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	3.81e-05	0.000257	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	3.64e-05	0.000245	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RAF1—dilated cardiomyopathy	3.42e-05	0.000231	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.3e-05	0.000222	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	3.19e-05	0.000215	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CD36—dilated cardiomyopathy	3.1e-05	0.000209	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.93e-05	0.000198	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	2.84e-05	0.000192	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.8e-05	0.000188	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	2.52e-05	0.00017	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGFR—dilated cardiomyopathy	2.35e-05	0.000158	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	1.95e-05	0.000131	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.73e-05	0.000117	CbGpPWpGaD
